Wedbush Issues Optimistic Forecast for KNSA Earnings

Key Points

• Wedbush raised its Q3 2025 EPS forecast for Kiniksa Pharmaceuticals International to $0.44, with a current price objective of $44.00 and an "Outperform" rating.
• The stock has seen a decrease of 2.3%, with its current market price opening at $37.03 after hitting a 12-month high of $39.43.
• Multiple analysts have varying ratings for Kiniksa, with a consensus rating of "Moderate Buy" and a price target average of $45.43.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) - Research analysts at Wedbush lifted their Q3 2025 EPS estimates for Kiniksa Pharmaceuticals International in a research report issued to clients and investors on Monday, October 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $0.44 for the quarter, up from their previous estimate of $0.43. Wedbush has a "Outperform" rating and a $44.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals International's current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals International's Q4 2025 earnings at $0.49 EPS, FY2025 earnings at $1.30 EPS, Q1 2026 earnings at $0.50 EPS, Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.64 EPS, Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $2.43 EPS, FY2027 earnings at $3.26 EPS and FY2028 earnings at $3.39 EPS.

Several other equities research analysts have also issued reports on KNSA. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They issued a "buy" rating and a $60.00 price target on the stock. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an "overweight" rating in a research note on Thursday, September 25th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Finally, Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $45.43.

Kiniksa Pharmaceuticals International Stock Down 2.3%

Shares of NASDAQ:KNSA opened at $37.03 on Tuesday. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $39.43. The company's fifty day simple moving average is $35.39 and its 200 day simple moving average is $29.36. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of 925.98 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC raised its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after buying an additional 532 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $31,000. USA Financial Formulas acquired a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at approximately $32,000. Finally, US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $33,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $415,147.14. The trade was a 86.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ross Moat sold 3,523 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the completion of the sale, the insider owned 9,415 shares of the company's stock, valued at $332,443.65. This trade represents a 27.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 584,471 shares of company stock worth $19,892,061. 53.48% of the stock is currently owned by corporate insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.